Rivastigmine

Generic Name: Rivastigmine

Brand Names: Exelon, Nimvastid, Prometax, Rivastigmine Sandoz, Rivastigmine 1 A Pharma, Rivastigmine Hexal, Rivastigmine Actavis

Drug Type: Small Molecule

Chemical Formula: C_₁₄H_₂₂N_₂O_₂

CAS Number: 123441-03-2

Unique Ingredient Identifier: PKI06M3IW0

Background: Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.

Indication: For the treatment of mild to moderate dementia associated with Parkinson's disease or of the Alzheimer's type.

Associated Conditions: Dementia With Lewy Body Disease, Mild Dementia due to Parkinson's disease, Mild Dementia of the Alzheimer's Type, Moderate Alzheimer's Type Dementia, Moderate Dementia due to Parkinson's disease

Clinical Trials

Safety, Tolerability, and Pharmacokinetic Study of EVP-6124 in Patients With Alzheimer's Disease

Phase 1

Completed

Conditions: Alzheimer's Disease
Central Nervous System Diseases

Interventions: Drug: EVP-6124 (0.1 mg/day)
Drug: EVP-6124 (1.0 mg/day)
Drug: EVP-6124 (0.3 mg/day)
Drug: Donepezil
Drug: Rivastigmine

First Posted Date: 2008-10-03

Last Posted Date: 2012-04-20

Lead Sponsor: FORUM Pharmaceuticals Inc

Target Recruit Count: 49

Registration Number: NCT00766363

Locations: 🇺🇸
Comprehensive Clinical Research, Berlin, New Jersey, United States
🇺🇸
Global Medical Institutes, LLC, Princeton, New Jersey, United States
🇺🇸
Pacific Research Network, Inc., San Diego, California, United States

and more 1 locations

Efficacy of Rivastigmine in Patients With Down Syndrome

Not Applicable

Completed

Conditions: Down Syndrome

Interventions: Drug: Rivastigmine

First Posted Date: 2008-09-08

Last Posted Date: 2012-11-28

Lead Sponsor: National Taiwan University Hospital

Target Recruit Count: 14

Registration Number: NCT00748007

Locations: 🇨🇳
Department of Medical Genetics, National Taiwan University Hospital, Taipei, Taiwan

Compliance and Tolerability of Rivastigmine Transdermal Patch 10 cm² in Patients With Probable Alzheimer's Disease.

Phase 4

Completed

Conditions: Alzheimer's Disease

Interventions: Drug: Rivastigmine transdermal patch

First Posted Date: 2008-08-08

Last Posted Date: 2017-03-28

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 380

Registration Number: NCT00731224

Locations: 🇹🇷
Novartis Investigative Site, Uskudar / Istanbul, Turkey

Rivastigmine for Intensive Care Unit (ICU) Delirium

Phase 4

Terminated

Conditions: Delirium

Interventions: Drug: Placebo
Drug: Rivastigmine

First Posted Date: 2008-06-24

Last Posted Date: 2010-08-13

Lead Sponsor: UMC Utrecht

Target Recruit Count: 104

Registration Number: NCT00704301

Locations: 🇳🇱
Medical Center Leeuwarden, Leeuwarden, Friesland, Netherlands
🇳🇱
Gelre Hospitals; lukas site, Apeldoorn, Gelderland, Netherlands
🇳🇱
Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands

and more 3 locations

RIVastigmine In Vascular cognitivE Impairment

Phase 4

Completed

Conditions: Cognitive Impairment

Interventions: Drug: Exelon (rivastigmine)
Drug: Placebo

First Posted Date: 2008-04-30

Last Posted Date: 2017-02-10

Lead Sponsor: Singapore General Hospital

Target Recruit Count: 50

Registration Number: NCT00669344

Locations: 🇸🇬
Singapore General Hospital, Singapore, Singapore

Rivastigmine in Mild Alzheimer's Disease, FMRI Study

Not Applicable

Completed

Conditions: Alzheimer' Disease

First Posted Date: 2008-03-03

Last Posted Date: 2011-10-28

Lead Sponsor: Kuopio University Hospital

Target Recruit Count: 20

Registration Number: NCT00627848

Locations: 🇫🇮
Kuopio University Hospital, Kuopio, Finland

A Double-Blind, Placebo-controlled Crossover Study of Repeat Rivastigmine Administration in Healthy Male Volunteers

Not Applicable

Completed

Conditions: Rivastigmine Toxicity

Interventions: Drug: Rivastigmine

First Posted Date: 2008-02-27

Last Posted Date: 2014-03-27

Lead Sponsor: Tel-Aviv Sourasky Medical Center

Target Recruit Count: 15

Registration Number: NCT00624663

Locations: 🇮🇱
Tasmc Clinical Research Center, Tel-Aviv, Israel
🇮🇱
Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm^2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)

Phase 4

Completed

Conditions: Alzheimer's Disease

First Posted Date: 2008-02-25

Last Posted Date: 2011-07-26

Lead Sponsor: Novartis

Target Recruit Count: 228

Registration Number: NCT00622713

Locations: 🇫🇷
Novartis Investigative Site, Rueil-Malmaison, France

Long-term Safety of Rivastigmine Capsule and Patch in Patients With Mild to Moderately-severe Dementia Associated With Parkinson's Disease (PDD)

Phase 3

Completed

Conditions: Parkinson's Disease Dementia

Interventions: Drug: Rivastigmine transdermal patch
Drug: Rivastigmine capsule

First Posted Date: 2008-02-25

Last Posted Date: 2011-11-28

Lead Sponsor: Novartis

Target Recruit Count: 583

Registration Number: NCT00623103

Locations: 🇺🇸
Collier Neurologic Specialists, Naples, Florida, United States
🇺🇸
Neurological Associates, Meridian, Idaho, United States
🇺🇸
Progressive Clinical Research, Bountiful, Utah, United States

and more 16 locations

Methylphenidate, Rivastigmine or Haloperidol in Hypoactive Delirium in Intensive Care Patients

Phase 3

Terminated

Conditions: Delirium

Interventions: Drug: Rivastigmine
Drug: Methylphenidate
Drug: Haloperidol

First Posted Date: 2008-01-23

Last Posted Date: 2018-03-21

Lead Sponsor: UMC Utrecht

Target Recruit Count: 80

Registration Number: NCT00599287

Locations: 🇳🇱
University Medical Center, Utrecht, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy